Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
false news
I checked their website
http://www.maximgrp.com/research/MaximUniverse.pdf
bcli is not upgraded
another 8k filed
http://www.sec.gov/Archives/edgar/data/1140098/000101968713001572/actc_8k.htm
Volation gets ~26 million shares at the rate of 6 cents per share.
More dilution. Is there a way to know how many such skeletons still exist in the closet? I am tired of these unpleasant surprises. I thought dilution was over after settling with camofi. But this thing doesn't seem to end. Is there a way to know if there are more Volations and Camofis out there in ACTC's closet?
Understanding Rabhin's game
Why did he not disclose his ~12 million sale over the past two years?
He feared, this will cause a downward spiral to the share price. The CEO of the company going on a selling spree does a lot of damage to investor confidence.
Why is selling?
A) He has lost trust in the ability to ACTC to deliver. If ACTC science is not all that promising then we are all doomed.
OR
B) He plans to allocate himself more shares in the near future. Goingforward, a large part of salary would come from stock ownership than hard cash.
We still have to lend him credit for the timing of disclosure. Had he disclosed this news early this year, it would be catastrophical. Most people like me are not selling ACTC seems to be at a very critical juncture awaiting the results of 20/100.
Failure to disclose required information may result in civil or criminal action
against persons involved for violations of the Federal securities laws and rules.
http://www.sec.gov/about/forms/form4data.pdf
Thankfully, I don't see any adverse consequences to the company (actc) itself. The violations are targeting actions against the person (rightly so).
sec form 4 alerts
Does any one know of a free website that sends alerts of form 4 filings of a particular company.
I am looking to keep tabs on any insider buy/sell activity. It gives clue on where this company is heading.
alerts to know when the ceo/owner sells his stock
Insider buying or selling is a very important indicator of the future of the company.
Let us say that Rabin sold his stock today and reported it promptly. How soon does it become public information. What is the best way to find that information. Is it possible to set any kind of alerts?
Rabin sold at highs most of the time
If you notice the charts, he sold during highs.
day traders in action today
They bumped up the pps in anticipation of rally. Seeing no action, they sold in the later half of the day.
I think the only point of real movement will come when they come out with results of 20/100. Could be either positive or negative.
how many shares is Rabin currently holding
This link says it is 6000001 ~ 6 million ( see column 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
http://secfilings.com/searchresultswide.aspx?link=2&filingid=9222122
However 10k says it is ~ 25 million shares.
http://secfilings.com/c.ashx?e=p0Ww1ld%2f1bWDgiajccY%2bZA%3d%3d&r=http%3a%2f%2fsecfilings.com%2fsearchresultswide.aspx%3flink%3d1%26filingid%3d9222116
6 million currently owned + 19 million shares subject to stock options that are currently exercisable or exercisable within 60 days of February 4, 2013.
Now the million dollar question is whether Rabin exercised his option or not? If he is really bullish then he should pounce on this opportunity, else he is just smooth talking and presenting a rosy picture.
a brief history of actc
http://www.nature.com/news/stem-cell-research-never-say-die-1.9759
I was wrongly assuming Stargardt's disease is same as wet amd.
However, the good thing is that Stargardt's disease is very much a part of the trials and has an orphan drug status. If the results turn out to be stellar, the drug could be marketed to Stargardt’s patients before phase III.
All really depends on how well the 20/100 patients respond to 150 RPE injections. In Lanza's own words
"We have that advantage as well as a very small number of cells going into a very local area. So we’re putting these into an area, we know where they are, and we know they’ll stay there, and, equally as important, we have instruments that enable us to look into the eye and actually see the retinal cells. So we can actually monitor, in real time, what’s going on in these patients. If there is any infiltrate or any adverse affects, we would hopefully be able to see it directly"
http://www.advancedcell.com/news-and-media/press-releases/advanced-cell-technologys-rpe-cells-granted-orphan-drug-status-from-fda-for-treatment-of-stargardts-m/
I think we are at a critical juncture and feel very bullish about this stock. Little downside for at least next few months and huge upward potential because of 20/100.
ACTC is Orphan Drug for wet amd
If phase II turns out to be spectacular, FDA will allow sale of this drug for wet amd patients.
another sec filing
http://ih.advfn.com/p.php?pid=nmona&article=56823599
It says "Notice of Effectiveness". Wonder what that means?
I googled and found this on yahoo
http://answers.yahoo.com/question/index?qid=1006053006343
Does that mean SEC has given a okay to uplist to Nasdaq. If true, does it mean actc has settled its dispute with SEC?
dry AMD engraftment question
I am not sure if Dry AMD patients showed engraftment or not. The Lancet publication clearly states that it was NOT observed for Dry AMD patients but still somehow resulted in improved visual improvement.
Lancet publication was done last year. I am not sure if they were able to ascertain engraftment in Dry AMD after the lancet publication. If anyone knows better, can you please post the relevant link?
Reference -
http://advancedcell.com/news-and-media/press-releases/act-publishes-first-report-of-embryonic-stem-cell-esc-derived-cells-transplanted-into-patients/index.asp
" Engraftment and increasing pigmentation were not detected in the dry AMD patient"
how to play this stock short term
I don't anticipate much in terms of good news in the month of March.
The anticipation of reverse-split announcement and selling of camofi shares would continue the downward trend.
In April, just before announcement of reverse split, Rabin will announce a good news about the 8o/100 trials. This will give a temporary boost to the pps. I recommend buying in april and selling just after good news.
misleading PR
Don't assume that Lanza has moved out of ACTC
I checked wikipedia and actc website and a few other internet resources. Nothing suggests that he has left actc.
http://www.advancedcell.com/robert-lanza.aspx
http://en.wikipedia.org/wiki/Robert_Lanza
http://www.robertlanza.com/
stop speculating
Why always point fingers at CAMOFI?
With an average daily volume of 13 million it will not be very difficult to sneak in 1 million shares during the course of the day.
We don't know it is CAMOFI and therefore should not assume it.
cancellation of reverse split caused a rally
Gary misspoke when he said that cancellation of reverse split caused the stock to go down. On the contrary, it went up once the news of cancellation was out.
"Gary - First we should understand that the stock performed horribly after we announced that we weren't going to do the split. I recognize that there is a small, but vocal, group of investors that think the reverse split and the NASDAQ listing is not a good thing. Those people are wrong."
Then u r not thinking like a owner but like a trader.
That's a big RED flag. Selling over10 million shares cannot be simply for taxes. If the founder does not trust the company then what good is it.
That's just two months back. I mean why would any insider want to dump even a single share when (supposedly) so many exciting things are bound to happen.
Lanza dumping his shares
Holy Shit!!!
http://secfilings.com/c.ashx?e=ohQwwfnAq%2bODgiajccY%2bZA%3d%3d&r=http%3a%2f%2fsecfilings.com%2fsearchresultswide.aspx%3flink%3d2%26filingid%3d9056422
Why the hell is he dumping them? Am I wrong in assessing the true worth of this company?
Mr Market is irrational.
This company is interesting but market does not see it yet
it's a big difference because
the better vision cohorts run PARALLEL to other cohorts.
It will take approximately 6 weeks + 4 weeks to complete the better vision cohort. Assuming the enrollment begins in 15 days, the better vision review results could be out in about 3 months. I am extremely bullish about the results. Earnest advise - DO NOT SELL NOW.
"Patients will be enrolled sequentially, and within each cohort of 3 patients, each patient's clinical course over the first 6 weeks following cell transplantation will be reviewed by an independent (DSMB) before enrollment is opened for the next 2 patients. A full safety assessment of all 3 patients in each cohort will be made by the DSMB when the 3rd patient in each cohort completes 4 weeks of follow-up, and before the first patient in the next cohort receives a cell transplant"
Stop this FUD
Fear, uncertainty and doubt (FUD).
It's reached a point where it makes me feel sick
Please point me to a reliable internet source for this comment "About a year and a half ago during one of the conferences, the head doctor (Schwartz) slipped up by informing the world that less than 10% of the cells injected survived, and before they made an adjustment, ZERO of the cells survived."
Both Lanza and RB have repeatedly told that visual acuity gains initially observed in all patients have been RETAINED even after more than an year.
It is impossible to achieve this result without engraftment. If all the cells died then all the patients should have turned blind again.
not before SEC settlement
queries regarding debentures
1) Can Camofi demand that the debentures be converted into stock options. If yes, then this could lead to more dilution.
2) 8k states "The quarterly payments may, at the option of the Company and subject to the satisfaction of certain conditions, be paid in shares of Common Stock. In such case, the conversion price for such payment will be based on the lesser of (i) the Conversion Price or (ii) 80% of the average of the 10 closing prices immediately prior to the date the quarterly payment is due"
What does Conversion Price mean?
Definition of 'Convertible Debenture'
A type of loan issued by a company that can be converted into stock by the holder and, under certain circumstances, the issuer of the bond. By adding the convertibility option the issuer pays a lower interest rate on the loan compared to if there was no option to convert. These instruments are used by companies to obtain the capital they need to grow or maintain the business.
Read more: http://www.investopedia.com/terms/c/convertibledebenture.asp#ixzz2J5bexDCG
8k reference:
The Debentures accrue interest at the rate of 8% per annum and mature on June 30, 2015. The Company may pre-pay all or a portion of the amounts due under the Debentures prior to maturity without penalty. Both of the Debentures are convertible at the option of the holder at a price per share of Common Stock equal to 80% of the VWAP of the ten consecutive trading days prior to the conversion date (the “Conversion Price”). The Company must make quarterly payments under the Debentures on the last day of each calendar quarter commencing on March 31, 2013 in the amount of $473,278. The quarterly payments may, at the option of the Company and subject to the satisfaction of certain conditions, be paid in shares of Common Stock. In such case, the conversion price for such payment will be based on the lesser of (i) the Conversion Price or (ii) 80% of the average of the 10 closing prices immediately prior to the date the quarterly payment is due. To secure its obligations under the Debentures, the Company will grant a security interest in substantially all of the Company’s assets, including its intellectual property, to the Settling Parties. The Debentures contain certain covenants customary for debt instruments of its kind.
Rocky301 - Take a bow
I read a lot of your previous messages. I strongly encourage all others who still haven't.
Your dd is par excellence.
I am bullish about this stock but having seen other stocks like Dendron, volatility seems to be the norm.
I am interested in knowing your strategy for ACTC. Do you plan to simply plan to buy on the dips and wait for the stock to eventually go up?
Or
Would you assume the stock will be volatile and have a strategy to cash on it?
Basically what is your game plan to maximize returns on this gem?
how do u read this settlement?
good or bad deal for ACTC?
White swans make this a Buy
Here is a list of possible white swans
Nih funding for its programmes.
Very favorable partnership deal.
Excellent results for 20\100 vision patents
Fast track fda approval because of act status.
No chances of any bad news atleast for next 6 months until the phase 2 results r out.
I think it is a screaming buy at these levels
Proof of insider selling please
On the contrary insiders have bought shares two weeks back
Icell-Board information is wrong??
Why is the clinicaltrials.gov website not updated yet?
Ind filing is due for this month.
The pps will rise on the news and they will reverse split 80:1
It is good to sell it on the news and buy back some after the reverse split.
already patented by actc and other stem cell pioneers
The company is most likely as scam company because patents on pluri potent stem cells is already held by other players.
Smd should not be ignored. It has good market.
Vision improvements have persisted in amd. Can it happen without grafting?
someone is dumping shares
I have been noticing a consistent trend for the last few days - large sell volume and low buy volume.
Be greedy when others are fearful
~ Warren Buffett
science stream becoming part of film plot is is a bullish sign.
It is a sign of growing acceptance and recognition of science by lay man.
This is indeed a very sweet spot.
Very less downside in terms of the financials (read dilution and going concerns)
Bad news of the trials will kill this stock. But its already so low that it really doesn't matter.
But good news can make this one take off like rocket.
So take your position guys. Sweet spots are very hard to find. Not every one of us is Buffett.
This reverse split unlike the other ones will actually cause a spike in the share price.
We don't have any institutional investors today. But after reverse split these dogs will come salivating.